Daidzein-metabolizing phenotypes in relation to bone density and body composition among premenopausal women in the United States

Atkinson, Charlotte; Newton, Katherine M.; Yong, Mellissa; Stanczyk, Frank Z.; Westerlind, Kim C.; Li, Lin; Lampe, Johanna W.

doi:10.1016/j.metabol.2012.05.012

Cited by 12 publications

(8 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, in a low-soy consuming population of overweight, postmenopausal women, ODMA non-producers, compared with ODMA producers, had lower bone mineral density (BMD), lower mammographic density, and lower 2-hydroxyestrone concentrations 15, 23, 24 . However, in similar work with an also low-soy consuming normal weight, premenopausal women, associations with the ODMA-producer phenotype were null for BMD, urinary estrogen metabolites, and mammographic density 25–27 . Here, we observed that obese individuals were approximately three-times more likely to be ODMA non-producers in a population that included a wide age range and males, premenopausal females, and postmenopausal females.…”

Section: Discussionmentioning

confidence: 91%

Obesity prevalence in relation to gut microbial environments capable of producing equol or O-desmethylangolensin from the isoflavone daidzein

et al. 2014

View full text Add to dashboard Cite

Background Studies have observed associations between the gut microbiome and obesity. O-desmethylangolensin (ODMA) and equol are gut bacterial metabolites of daidzein, a compound found in high amounts in soy foods. Approximately 80–95% and 25–60% of individuals harbor gut microbial communities capable of producing ODMA or equol, respectively. Given that other phenotypes of gut bacterial metabolism of dietary compounds have been associated with obesity, we hypothesized that daidzein-metabolizing phenotypes would be associated with obesity. Objective To compare the prevalence of ODMA-producer and equol-producer phenotypes in obese, overweight, and normal weight individuals. Methods Adults aged 18 to 95 years (n=297) provided a first-void urine sample after a three-day soy challenge, and urinary ODMA and equol concentrations were used to classify individuals as producers or non-producers. Body mass index was calculated from self-reported weight and height. Results There were 60 ODMA non-producers and 173 equol non-producers. Obese individuals were 2.8-times more likely to be ODMA non-producers (OR=2.8, 95% CI: 1.2, 6.2) compared to normal weight individuals, when adjusted for age, race (white vs. non-white), and gender and menopausal status (male, premenopausal female, and postmenopausal female). Obesity was not associated with equol-producer phenotype (OR=1.1, 95% CI: 0.5, 2.2). Stronger associations with obesity were observed in the ODMA non-producers who were also equol producers than equol non-producers. Conclusions Results from this analysis suggest that the ODMA-producer phenotype, but not equol-producer phenotype, is associated with obesity in adults. These results support further work to replicate these findings and evaluate mechanisms of the observed associations.

show abstract

Section: Discussionmentioning

confidence: 91%

Obesity prevalence in relation to gut microbial environments capable of producing equol or O-desmethylangolensin from the isoflavone daidzein

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Thus, obesity has been correlated with the non equol-producer phenotype [187]. In addition, a positive correlation has been observed in the cardiovascular risk profiles and the equol-producer phenotype in pre-hypertensive postmenopausal women [188]. …”

Section: Discussionmentioning

confidence: 99%

Meta-Analysis of the Effects of Foods and Derived Products Containing Ellagitannins and Anthocyanins on Cardiometabolic Biomarkers: Analysis of Factors Influencing Variability of the Individual Responses

Garcı́a-Conesa

Chambers

Combet

et al. 2018

IJMS

119

107

View full text Add to dashboard Cite

Understanding interindividual variability in response to dietary polyphenols remains essential to elucidate their effects on cardiometabolic disease development. A meta-analysis of 128 randomized clinical trials was conducted to investigate the effects of berries and red grapes/wine as sources of anthocyanins and of nuts and pomegranate as sources of ellagitannins on a range of cardiometabolic risk biomarkers. The potential influence of various demographic and lifestyle factors on the variability in the response to these products were explored. Both anthocyanin- and ellagitannin-containing products reduced total-cholesterol with nuts and berries yielding more significant effects than pomegranate and grapes. Blood pressure was significantly reduced by the two main sources of anthocyanins, berries and red grapes/wine, whereas waist circumference, LDL-cholesterol, triglycerides, and glucose were most significantly lowered by the ellagitannin-products, particularly nuts. Additionally, we found an indication of a small increase in HDL-cholesterol most significant with nuts and, in flow-mediated dilation by nuts and berries. Most of these effects were detected in obese/overweight people but we found limited or non-evidence in normoweight individuals or of the influence of sex or smoking status. The effects of other factors, i.e., habitual diet, health status or country where the study was conducted, were inconsistent and require further investigation.

show abstract

“…The interindividual differences in metabolizing the isoflavone daidzein to equol or O-desmethyl-angolensin (ODMA) might explain the discrepancy of the soy/isoflavones effects on human health (cardiovascular, obesity, bone density, etc.). For example, the ODMA-producer phenotype, but not the equol-producer phenotype, has been associated with obesity in adults [113] but not with bone density and body composition [114]. In addition, equol/ODMA producers had more favorable cardiovascular risk profiles than nonproducers in Chinese prehypertensive postmenopausal women [100].…”

Section: Is There a Parallelism Between Urolithin Metabotypes And Isomentioning

confidence: 98%

Urolithins, the rescue of “old” metabolites to understand a “new” concept: Metabotypes as a nexus among phenolic metabolism, microbiota dysbiosis, and host health status

Tomás-Barberán

González‐Sarrías

Garcı́a-Villalba

et al. 2016

Molecular Nutrition Food Res

359

384

View full text Add to dashboard Cite

Urolithins are dibenzo[b,d]pyran-6-one derivatives that are produced by the human gut microbiota from ellagitannins and ellagic acid (EA). These metabolites are much better absorbed than their precursors and have been suggested to be responsible for the health effects attributed to ellagitannins and EA that occur in food products as berries and nuts. In the present review, the role and potential of urolithins in human health are critically reviewed, and a perspective of the research approach needed to demonstrate these health effects is presented, based on the existing knowledge. The analytical methods available for urolithin analysis, their occurrence in different tissues and biological fluids, and their metabolism by human gut microbiota are considered. In addition, the interindividual variability observed for the production of urolithins (metabotypes) and its relationship with health status and dysbiosis are also reviewed. The potential mechanisms of action of urolithins are also critically discussed, paying attention to the concentration and the type of metabolites used in the in vitro and in vivo assays and the physiological significance of the results obtained. The gut microbiota metabolism of EA to urolithins and that of daidzein to equol, their individual variations, and the effects on health are also compared.

show abstract

Daidzein-metabolizing phenotypes in relation to bone density and body composition among premenopausal women in the United States

Cited by 12 publications

References 22 publications

Obesity prevalence in relation to gut microbial environments capable of producing equol or O-desmethylangolensin from the isoflavone daidzein

Obesity prevalence in relation to gut microbial environments capable of producing equol or O-desmethylangolensin from the isoflavone daidzein

Meta-Analysis of the Effects of Foods and Derived Products Containing Ellagitannins and Anthocyanins on Cardiometabolic Biomarkers: Analysis of Factors Influencing Variability of the Individual Responses

Urolithins, the rescue of “old” metabolites to understand a “new” concept: Metabotypes as a nexus among phenolic metabolism, microbiota dysbiosis, and host health status

Contact Info

Product

Resources

About